Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals
10.1097/CM9.0000000000002917
- VernacularTitle:Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals
- Author:
Xiaoxu HAN
1
;
Jin SUN
;
Yihang ZHANG
;
Taiyi JIANG
;
Qingshan ZHENG
;
Haiyan PENG
;
Yao WANG
;
Wei XIA
;
Tong ZHANG
;
Lijun SUN
;
Xinming YUN
;
Hong QIN
;
Hao WU
;
Bin SU
Author Information
1. Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
- Keywords:
Human immunodeficiency virus;
Ainuovirine;
Population pharmacokinetics;
Expose-response model;
Safety;
Acquired immune deficiency syndrome;
Antiretroviral t
- From:
Chinese Medical Journal
2024;137(20):2473-2482
- CountryChina
- Language:Chinese
-
Abstract:
Background::Ainuovirine (ANV) is a new generation of non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus (HIV) type 1 infection. This study aimed to evaluate the population pharmacokinetic (PopPK) profile and exposure-response relationship of ANV among people living with HIV.Methods::Plasma concentration-time data from phase 1 and phase 3 clinical trials of ANV were pooled for developing the PopPK model. Exposure estimates obtained from the final model were used in exposure-response analysis for virologic responses and safety responses.Results::ANV exhibited a nonlinear pharmacokinetic profile, which was best described by a two-compartment model with first-order elimination. There were no significant covariates correlated to the pharmacokinetic parameters of ANV. The PopPK parameter estimate (relative standard error [%]) for clearance adjusted for bioavailability (CL/F) was 6.46 (15.00) L/h, and the clearance of ANV increased after multiple doses. The exposure-response model revealed no significant correlation between the virologic response (HIV-RNA <50 copies/mL) at 48 weeks and the exposure, but the incidence of adverse events increased with the increasing exposure ( P value of steady-state trough concentration and area under the steady-state curve were 0.0177 and 0.0141, respectively). Conclusions::Our PopPK model supported ANV 150 mg once daily as the recommended dose for people living with HIV, requiring no dose adjustment for the studied factors. Optimization of ANV dose may be warranted in clinical practice due to an increasing trend in adverse reactions with increasing exposure.Trial registration::Chinese Clinical Trial Registry https://www.chictr.org.cn (Nos. ChiCTR1800018022 and ChiCTR1800019041).
